You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Medtronic
Harvard Business School
AstraZeneca
Boehringer Ingelheim

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

TAZORAC Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Tazorac patents expire, and what generic alternatives are available?

Tazorac is a drug marketed by Allergan and is included in two NDAs.

The generic ingredient in TAZORAC is tazarotene. There are eight drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the tazarotene profile page.

US ANDA Litigation and Generic Entry Outlook for Tazorac

A generic version of TAZORAC was approved as tazarotene by TARO PHARMS on April 3rd, 2017.

  Start Trial

Drug patent expirations by year for TAZORAC
Drug Prices for TAZORAC

See drug prices for TAZORAC

Drug Sales Revenue Trends for TAZORAC

See drug sales revenues for TAZORAC

Recent Clinical Trials for TAZORAC

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dana-Farber Cancer InstitutePhase 2
BayerPhase 2
Dr. Reddy's Laboratories LimitedPhase 2

See all TAZORAC clinical trials

Pharmacology for TAZORAC
Drug ClassRetinoid

US Patents and Regulatory Information for TAZORAC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan TAZORAC tazarotene CREAM;TOPICAL 021184-001 Sep 29, 2000 RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-002 Jun 13, 1997 RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan TAZORAC tazarotene CREAM;TOPICAL 021184-002 Sep 29, 2000 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-001 Jun 13, 1997 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TAZORAC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-002 Jun 13, 1997   Start Trial   Start Trial
Allergan TAZORAC tazarotene CREAM;TOPICAL 021184-001 Sep 29, 2000   Start Trial   Start Trial
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-002 Jun 13, 1997   Start Trial   Start Trial
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-001 Jun 13, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for TAZORAC

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0284288 SPC/GB98/002 United Kingdom   Start Trial PRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730
0284288 12/1998 Austria   Start Trial PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: 1-22102, 1-22103 19970918; FIRST REGISTRATION: DE 37393.00.00, 37393.01.00 19961203
0031058 98C0008 Belgium   Start Trial PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: NL22604 19970922; FIRST REGISTRATION: DE - 37393.00.00 19961203
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Moodys
Colorcon
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.